Abstract
The relationship between estrogen (E2) and carcinoma of the breast has been appreciated for nearly 100 years. In the late nineteenth century, Beatson reported that patients with inoperable breast tumors frequently responded to surgical castration [1], still a first-line therapeutic modality in premenopausal patients. Other manipulations designed to lower the concentrations of circulating E2 or to block its effects are also as effective, inducing remissions in about 30% –40% of patients [2]. Since alternative treatments are available for breast cancer patients, it is important for clinicians to consider all available biological factors that can predict which of these women are likely to respond to hormonal treatments. Among these variables, the estrogen receptor (ER) is the most important in predicting response to hormonal treatments. Multiple clinical studies show that those patients whose tumors express ER have a 70%–80% chance of response, compared to only 10% in those that do not [3–5].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Beatson GT. 1896. On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment with illustrative cases. Lancet 3: 104–107.
Osborne CK. 1991. Receptors. In Harris JR, Hellman S, Henderson IC, Kinne DW (eds). Breast Diseases. J.B. Lippincott: Philadelphia.
Edwards DP, Chamness GC, McGuire WL. 1979. Estrogen and progestcrone receptor proteins in breast cancer. Biochim Biophys Acta 560: 457–486.
McGuire WL. 1980. The usefulness of steroid hormone receptors in the management of primary and advanced breast cancer. In Mouridson HT, Palshof T (eds), Breast Cancer: Experimental and Clinical Aspects. Pergamon Press: New York.
McGuire WL, Chamness GC, Fuqua SAW. 1991. Estrogen receptor variants in clinical breast cancer. Mol Endocrinol 5: 1571–1577.
Gorski J, Toft DO, Shyamala G. 1968. Hormone receptors: Studies on the interaction of estrogen with uterus. Recent Prog Horm Res 24: 45–80.
Jensen EU, DeSombre ER. 1972. Mechanisms of action of the female sex hormones. Annu Rev Biochem 41: 203–230.
Walter P, Green S, Greene G, Krust A, Bornet J-M, Jeltsch JM, Staub A, Jensen E, Scrace G, Waterfield M, Chambon P. 1985. Cloning of the human estrogen receptor cDNA. Proc Natl Acad Sci USA 82: 7889–7893.
Green S, Walter P, Kumar V, Krust A, Bornet J-M, Argos P, Chambon P. 1986. Human oestrogen receptor cDNA: Sequence, expression, and homology to v-erb-A. Nature 320: 134–139.
Evans RM. 1988. The steroid and thyroid hormone receptor family. Science 240: 889–895.
Krust A, Green S, Argos P, Kumar V, Walter P, Bornet J-M, Chambon P. 1986. The chicken oestrogen receptor sequence: Homology with v-erb-A and the human oestrogen and glucocorticoid receptors. EMBO J 5: 891–897.
White R, Lees JA, Needham M, Ham J, Parker MG. 1987. Structural organization and expression of the mouse estrogen receptor. Mol Endocrinol 1: 735–744.
Kumar V, Green S, Stack G, Berry M, Jin J-R, Chambon P. 1987. Functional domains of the human estrgoen receptor. Cell 51: 941–951.
Lees JA, Fawell SE, Parker MG. 1989. Identification of two transactivation domains in the mouse oestrogen receptor. Nucleic Acids Res 17: 5477–5488.
Tora L, White J, Brou C, Tasset D, Webster N, Scheer E, Chambon P. 1989. The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell 59: 477–487.
White JH, Metzger D, Chambon P. 1988. Expression and function of the human estrogen receptor in yeast. Cold Spring Harbor Symp Quant Biol 53: 819–828.
Evans RM, Hollemberg SM. 1988. Zinc fingers: Guilt by association. Cell: 52: 1–3.
Green S, Kumar V, Theulaz I, Wahli W, Chambon P. 1988. The N-terminal DNA-binding ‘zinc finger’ of the oestrogen and glucocorticoid receptors determines target gene specificity. EMBO J 7: 3037–3044.
Ponglikitmonkgol M, Green S, Chambon P. 1988. Genomic organization of the human oestrogen receptor gene. EMBO J 7: 3385–3388.
Green S, Chambon P. 1987. Oestradiol induction of a glucocorticoid-responsive gene by a chymeric receptor. Nature 325: 75–78.
Mader S, Kumar V, DeVerneuil H, Chambon P. 1989. Three amino acids of the oestrogen receptor are essential to its ability to distinguish an estrogen from a glucocorticoid-responsive element. Nature 338: 271–274.
Umesono K, Evans R. 1989. Determinants of target gene specificity for steroid/thyroid hormone receptors. Cell 57: 1139–1146.
Danielsen M, Hinck L, Ringold GM. 1989. Two amino acids within the knuckle of the first zinc finger specify DNA responsive element activation by the glucocorticoid receptor. Cell 57: 1131–1138.
Green S, Chambon P. 1991. The oestrogen receptor: From perception to mechanism. In Parker MG (ed), Nuclear Hormone Receptors. Molecular Mechanisms, Cellular Functions, Clinical Abnormalities. Academic Press: San Diego.
Kumar V, Chambon P. 1988. The estrogen receptor binds tightly to its responsive element as a ligand-induced homodymer. Cell 55: 145–156.
Chambraud B, Berry M, Redeuilh G, Chambon P, Baulieu EE. 1990. Several regions of the human estrogen receptor are involved in the formation of receptor-heat shock protein 90 complexes. J Biol Chem 265: 20686–20691.
Damm K, Berg H, Graft T, Vennestrom B. 1987. A single point mutation in erbA restores the transforming potential of a mutant avian erythroblastosis virus (AEV) defective in both erbA and erbB oncogenes. EMBO J 6: 375–382.
Katzenellenbogen BS, Elliston JF, Monsma FJ, Springer PA, Ziegler YS, Greene GL. 1987. Structural analysis of covalently labeled estrogen receptors by limited proteolysis and monoclonal antibody reactivity. Biochemistry 26: 2364–2373.
Berry M, Metzger D, Chambon P. 1990. Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J 9: 2811–2818.
Tzukerman M, Zhang X-K, Hermann T, Wills KN, Graupner G, Pfahl M. 1990. The human estrogen receptor has transcriptional activator and repressor functions in the absence of ligand. New Biologist 2: 613–620.
Fritsch M, Welch RD, Murdoch FE, Anderson I, Gorski J. 1992. DNA allosterically modulates the steroid-binding domain of the estrogen receptor. J Biol Chem 267: 1823–1828.
Martin MB, Saceda M, Lindsey RK. 1991. Estrogen and progesterone receptors. In Lippman M, Dickson R (eds), Regulatory Mechanisms in Breast Cancer. Kluwer Academic Publishers: Boston.
Catelli MG, Binart N, Jung-Testas I, Renoir J-M, Balieu EE, Feraminsco JR, Welch WJ. 1985. The common 90-kD protein component of non-transformed ‘8S’ steroid receptors is a heat shock protein. EMBO J 4: 3131–3135.
Binart N, Chambraud B, Dumas B, Rowlands DA, Bigogne C, Levin JM, Gamier Baulieu EE, Castelli MG. 1989. The cDNA-derived amino acid sequence of chick heat shock protein Mr 90,000 (hsp90) reveals a ‘DNA like’ structure: Potential site of interaction with steroid receptors. Biochem Biophys Res Commun 159: 140–147.
Fawell SE, Lees JA, White R, Parker MG. 1990. Characterization and co-localization of steroid-binding and dimerization activities in the mouse estrogen receptor. Cell 60:953–962.
Early Breast Cancer Trialists Collaborative Group. 1992. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 339:1–15.
Rose C, Thorpe SM, Anderson KW, Pedersen BV, Mouridsen HT, Blichert-Toft M, Rasmussen BB. 1985. Beneficial effect of tamoxifen in primary breast cancer patients with high estrogen receptor values. Lancet 1: 16–18.
Glauber JG, Kiang DT. 1992. The changing role of hormonal treatment in advanced breast cancer. Semin Oncol 19: 308–316.
Harper MJK, Walpole AL. 1967. A new derivative of triphenylethylene: Effect on implantiation and mode of action in rats. J Reprod Fertil 13: 101–119.
Labhsetwar AP. 1970. Role of estrogen in ovulation. A study using the estrogen antagonist ICI 46,474. Endocrinology 87: 542–551.
Sutherland RL, Merter J, Baulieu EE. 1977. Tamoxifen is a potent ‘pure’ antiestrogen in the chick oviduct. Nature 267: 434–435.
Jordan VC, Phelps E, Lindgren JU. 1987. Effects of antiestrogens on bone in castrated and intact female rats. Breast Cancer Res Treat 10: 31–35.
Terenius L. 1971. Structure-activity relationship of antiestrogens with regard to interaction with 17b-oestradiol in the mouse uterus and vagina. Acta Endocrinol 66: 431–447.
Jordan VC, Robinson SP. 1987. Species-specific pharmacology of antiestrogens: Role of metabolism. Fed Proc 40: 1870–1874.
Turner RT, Wakely GK, Hannon KS, Bell NH. 1987. Tamoxifen prevents the skeletal effects of ovarian deficiency in rats. J Bone Miner Res 2: 449–456.
Love RR, Mazess RB, Tormey DC, Barden HS, Newcomb PA, Jordan VC. 1988. Bone mineral density in women with breast cancer treated for at least two years with tamoxifen. Breast Cancer Res Treat 12: 297–301.
Torken S, Siris E, Seldin D, Flaster E, Hyman G, Lindsay R. 1989. Effects of tamoxifen on spinal bone density in women with breast cancer. J Natl Cancer Inst 87: 1086–1088.
Bertelli G, Pronzoto P, Amoroso D. 1988. Adjuvant tamoxifen in primary breast cancer: Influence on plasma lipids and antithrombin III. Breast Cancer Res Treat 12: 307–310.
Buckley M, Goa KL. 1989. Tamoxifen: A reappraisal of its pharmacodynamic and pharma-cokinetic properites and therapeutic use. Drugs 37: 451–490.
Katzenellenbogen BS. 1992. Antiestrogen resistance: Mechanisms by which breast cancer cells undermine the effectivess of endocrine therapy. J Natl Cancer Inst 83: 1434–1435.
Osborne CK, Coronado E, Alfred DC, Wiebe V, DeGregorio M. 1991. Acquired tamoxifen resistance: Correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4 hydroxytamoxifen. J Natl Cancer Inst 83: 1477–1482.
Osborne CK, Wiebe VJ, McGuire WL, Ciocca DR, DeGregorio MW. 1992. Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients. J Clin Oncol 10: 304–310.
Wiebe VJ, Osborne CK, McGuire WL, DeGregorio MW. 1992. Identification of estrogenic tamoxifen metabolite(s) in tamoxifen resistant human breast tumors. J Clin Oncol 10: 990–994.
Murphy L, Dotzlaw H. 1989. Variant estrogen receptor mRNA species detected in human breast cancer biopsy samples. Mol Endocrinol 3: 687–693.
Graham ML II, Krett NL, Miller LA, Leslie KK, Gordon DF, Wood WM, Wei LL, Horwitz KB. 1990. T47DCO cells, genetically unstable and containing estrogen receptor mutations, are a model for the progression of breast cancer to hormone resistance. Cancer Res 50: 6208–6217.
Fuqua SAW, Fitzgerald SD, Allred DC, Elledge RM, Nawaz Z, McDonnell DP, O’Malley BW, Greene GL, McGuire WL. 1992. Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors. Cancer Res 52: 483–486.
Garcia T, Lehrer S, Bloomer WD, Schachter B. 1988. A variant estrogen receptor messenger ribonucleic acid is associated with reduced levels of estrogen binding in human mammary tumors. Mol Endocrinol 2: 785–791.
Garcia T, Sanchez M, Cox JL, Shaw PA, Ross JB, Lehrer S, Schachter B. 1989. Identification of a variant form of the human estrogen receptor with an amino acid replacement. Nuclei Acids Res 17: 8364.
Scott GK, Kushner P, Vigne JL, Benz CC. 1991. Truncated forms of DNA-binding estrogen receptors in human breast cancer. J Clin Invest 88: 700–706.
Wang Y, Micksicek RJ. 1991. Identification of a dominant negative form of the human estrogen receptor. Mol Endocrinol 5: 1707–1715.
Dotzlaw H, Alkhalaf M, Murphy LC. 1992. Characterization of estrogen receptor variant mRNA from human breast cancer. Mol Endocrinol 6: 773–785.
Karnik PS, Smith C, Tubbs RR, Bukowski RM. 1992. Variant estrogen receptors in tamoxifen resistant human breast cancer (abstract). Breast Cancer Res Treat 23: 184.
Fuqua SAW, Fitzgerald SD, Chamness GC, Tandon AK, McNonnell DP, Nawaz Z, O’Malley BW, McGuire WL. 1991. Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res 51: 105–109.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer Science+Business Media New York
About this chapter
Cite this chapter
Encarnacion, C.A., Fuqua, S.A.W. (1994). Estrogen receptor variants in breast cancer. In: Dickson, R.B., Lippman, M.E. (eds) Mammary Tumorigenesis and Malignant Progression. Cancer Treatment and Research, vol 71. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2592-9_6
Download citation
DOI: https://doi.org/10.1007/978-1-4615-2592-9_6
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6109-1
Online ISBN: 978-1-4615-2592-9
eBook Packages: Springer Book Archive